TNFAIP3 and systemic sclerosis: In both SSc-PF and IPF, the IL17 signaling pathway is enriched (Supplementary Figures 9, 11) and the expression of the ubiquitin-editing enzyme A20 (TNFAIP3), a major regulator of NFκB activation, is upregulated (43, 44).